104 results about "Chikungunya fever" patented technology

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention relates to a preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV). The method comprises the steps of: modifying genetic elements of a structural protein encoding gene C-E3-E2-6K-E1 of CHIKV, cloning the modified genetic elements into the expression vector of an insect cell, then transfecting the obtained recombined expression vector and baculovirus linear DNA respectively to an SF9 insect cell and making the cell secrete and express CHIKV VLPs. Additionally, the invention also makes preliminary studies on the immune effects of CHIKV VLPs and applicationof CHIKV VLPs in virus specific antibody detection, thus laying a foundation for research and preparation of immunological detection reagents and even vaccines based on CHIKV VLPs.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.

The invention provides a detection method of Chikungunya virus, which comprises the procedures as follows: pretreatment of test sample; RNA extraction of test sample to be detected; design and synthesis of primer and probe; determination of optimum fluorescence quantitative PCR reaction system; program amplification and adjudging results according to Ct value. The optimum fluorescence quantitative PCR reaction system is determined as follows: the CHIK-FP terminal concentration of positive primer is 500nM, the CHIK-RP terminal concentration of reverse primer is 1000nM, and the CHIK-Probe terminal concentration of probe is 250nM. The amplification program is 45 times of circulation of 10 minutes at 50 DEG C, 10 minutes at 95 DEG C, 10 seconds at 95 DEG C and 30 seconds at 62 DEG C. The invention establishes a detection method for Chikungunya virus, which can be applied on monitoring of the virus, and can further strengthen the monitoring work for preventing from spreading the disease into our country and has important social efficiency and economic efficiency.

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.

The invention discloses a kit for detecting a plurality of mosquito borne pathogens and a detection method thereof. The plurality of mosquito-borne infectious pathogens are detected by using multiplex polymerase chain reaction (PCR) combined with a liquid chip, and a yellow fever virus (YFV), dengue fever viruses (DV) I-IV type, epidemic encephalitis B (japanese encephalitis) virus (JEV), plasmodium (Plasmodium), (including plasmodium vivax (PV), plasmodium falciparum (PF), plasmodium malariae (PM), plasmodium ovale (PO)), a west nile virus (MNV) and a chikungunya virus (CHIKV) can be detected in parallel one time. The kit has the advantages of being large in flux, high in specificity and sensitivity, stable in result, good in repeatability, simple to operate and fast in detection speed.

The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.

The invention belongs to the field of microbial molecular detection, and particularly relates to a kit for flavivirus quick typing and virus load detection. The kit for flavivirus quick typing and virus load detection comprises specific primers and probes for flaviviruses, including specific primers and a probe for dengue virus, specific primers and a probe for Zika virus, specific primers and a probe for yellow fever virus, and specific primers and a probe for Chikungunya virus. The kit for flavivirus quick typing and virus load detection has the advantages of high detection speed and accurate detection and quantification results, can simultaneously detect 3 different flavivirus pathogens and 1 togavirus pathogen capable of causing similar clinical symptoms at one time, can detect and diagnose flavivirus-pathogen-infected suspicious cases in time, and enhances the detection accuracy of flavivirus pathogen infection.

The invention relates to the technical field of molecular biological detection of an insect-borne infectious disease, and discloses a triple real-time fluorescence RT-PCR detection method, primer and probe as well as kit of Zika virus, dengue virus and chikungunya virus. The primer comprises the sequences of SEQ ID No.1, SEQ ID No.2, SEQ ID No.4, SEQ ID No.5, SEQ ID No.7 and SEQ ID No.8; the probe comprises the sequences of SEQ ID No.3, SEQ ID No.6, and SEQ ID No.9; the kit comprises a primer probe mixed solution, an RT-PCR reaction solution, an enzyme mixed solution, and a positive standard substance. The Zika virus, the dengue virus and the chikungunya virus can be fast detected in the reaction solution of a same tube by use of a triple real-time fluorescence RT-PCR amplification technology by optimizing the reaction solution formula and the primer probe sequences, the single detection is unnecessary; compared with the traditional PCR detection method, the operation step is reduced, whether the reaction solution contains the three virus can be fast and accurately detected, the detection time is shortened, the detection efficiency is improved, and the cost is saved.

The invention discloses a nucleic acid detection kit for Zika virus, dengue fever virus and Chikungunya virus, and an application of the kit, wherein the kit includes: a RT-PCR reaction solution, an enzyme mixture liquid, a Zika virus / dengue fever virus / Chikungunya virus / endogenous reference gene quadruple reaction solution, a positive control, and a blank control. The kit can simultaneously detect the Zika virus, dengue fever virus and Chikungunya virus in one reaction and solves a problem that an in-vitro detection kit cannot simultaneously detect the Zika virus, dengue fever virus and Chikungunya virus in one reaction tube; besides, the detection kit is high in specificity and sensitivity, has simple operation, excellent repeatability and quick and objection detection results. The invention provides an effective technical means for in-vitro detection of the Zika virus, dengue fever virus and Chikungunya virus.

The invention discloses a new chikungunya virus fluorescence quantitative polymerase chain reaction (PCR) detection method and a chikungunya virus PCR detection system. The detection system consists of a primer and a probe, Premix Ex Taq reaction solution and sterilized Tris solution, wherein the primer and probe have good detection specificity. The system has high sensitivity, is very suitable for chikungunya virus and does not have cross reactions with the dengue virus and the like.

The invention concerns a new medicinal product for the treatment of chikungunya, i.e a concentrate of chikungunya-specific immunoglobulins, as well as its process of preparation.

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.

The invention relates to the technical field of virus detection, and concretely relates to a method for detecting Zika virus, Chikungunya virus and Mayaro virus by triple real-time fluorescent quantitative RT-PCR. The method combines the probability of occurrence of related mosquito-borne pathogens, the risk of prevalence, and the operability of a laboratory testing procedure, the Mayaro virus isused to replace the dengue virus in an existing common combination detection scheme, and a new detection scheme using Zika virus, Chikungunya virus and Mayaro virus as detection targets is formed. Theinvention provides a specific primer, a probe and a triple real-time quantitative RT-PCR detection method for simultaneously identifying the viral pathogens Zika virus, Chikungunya virus and Mayaro virus which are transmitted by Aedes mosquito and cause similar clinical symptoms of diseases. The method has high specificity and sensitivity, good repeatability, simple and rapid detection, and costsaving, and can complement a traditional detection scheme and has high application value.

Embodiments disclosed herein provide for antibodies, including neutralizing antibodies, against Chikungunya virus, uses thereof, and methods of identifying antibodies, including neutralizing antibodies, against Chikungunya virus. In some embodiments, antibodies that binds to a CHIKV antigen, wherein the antigen is the CHIKV E1, E2, E3 protein, or any heterocomplex thereof are provided. In some embodiments, the antibody is an isolated antibody, a neutralizing antibody, a recombinant antibody, or any combination thereof. In some embodiments, the antibodies described herein bind to an epitope of E2 Domain A, E2 Domain B, or E1 Domain II of the CHIKV antigen. In some embodiments, the antigen is E2 protein.

The invention relates to a hemorrhagic fever associated pathogen identifying gene chip; the preparation method comprises preparation of a specific primer, preparation of a pathogen specific oligonucleotide probe, preparation of an oligonucleotide chip, establishment of an RT-PCR (reverse transcription-polymerase chain reaction) system and establishment of a hybrid system and a signal detection method. The gene chip prepared by the invention can be used for simultaneously identifying 16 hemorrhagic fever associated pathogen microorganisms, including Zaire Ebola virus, Sudan Ebola virus, marburg virus, lassa virus, junin virus, Machupo virus, rift valley fever virus, Crimea-Congo hemorrhagic fever virus, plasmodium, hantaan virus, SFTS (severe fever with thrombocytopenia syndrome) virus, dengue virus, yellow fever virus, Chikungunya virus, influenza A virus and influenza B virus. The gene chip has the characteristics of being rapid and accurate, high in throughput and high in sensitivity; and a new technological means is offered for the diagnosis of hemorrhagic fever pathogen, health supervision and the control and prevention of infectious diseases.

The invention discloses an identification and detection method for yellow fever, Japanese encephalitis, chikungunya fever and west Nile fever, primers and probes. The identification and detection method comprises the step of rapidly, qualitatively and quantitatively detecting a yellow fever virus, a Japanese encephalitis virus, a chikungunya virus and a west Nile virus by combining polymerase chain reaction (PCR) and a liquid chip. The four pairs of primers and probes with high specificity, high sensitivity and good repeatability are provided in the method.

The invention discloses a fulminating-infectious-disease pathogen detecting primer pair and a kit. The primer pair comprises at least a pair of RT-LAMP primers of Ebola viruses, Lassa fever viruses, Marburg viruses, rift valley fever viruses, yellow fever viruses and Chikungunya fever viruses. By means of the primer system, the amplification reaction background is reduced, and sensitivity and specificity are quite good. The kit formed by the primer pair further comprises detecting liquid and a micro-fluidic chip; as an independent RT-PCR secondary amplification step of a detecting liquid system is omitted, detecting time is shortened; as the denaturation process and the renaturation process of nucleic acid do not exist, the polluted chance of RNA enzymes and the polluted chance of amplification nucleic acid are reduced, and the sensibility and the safety of detection are improved. By means of the constant-temperature sealed environment provided by a micro-fluidic chip system, rapid and constant-temperature amplification and automation result distinguishing of a nucleic acid extracting template are finally achieved, the requirement for test hardware is reduced, the use level of a reaction reagent is reduced, detection cost is reduced, and the result can be directly determined through color changes.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.

The invention relates to the technical field of biological detection, and in particular relates to a primer, a probe and a kit used for detecting dengue fever, chikungunya and yellow fever virus through a single tube by the multiplex-fluorescence PCR (Polymerase Chain Reaction). The primer and probe used for detecting the dengue fever, chikungunya and yellow fever virus through the multiplex-fluorescence PCR have nucleotide sequences as shown in SEQ ID NO: 1-9; the multiplex PCR detection kit for detecting the dengue fever, chikungunya and yellow fever virus comprises multiplex-fluorescence PCR detection mixed liquid which contains the primer and probe mentioned above. The kit, primer and probe can quickly detect the dengue fever virus, chikungunya virus and yellow fever virus, have the advantages of being simple and convenient to operate, high in sensitivity and outstanding in specificity, and can timely find out and confirm a suspect case so as to improve the monitoring level on such diseases.

The invention provides a chikungunya virus isothermal amplification detection kit and a primer thereof. The kit comprises the primer, Bst DNA polymerase, a reaction liquid and SYBR Green I fluorescent dye, wherein the reaction liquid is 10mM deoxyribonucleoside triphosphate, 10*reaction buffer liquid and 150mM MaSO4; the sequences of the primer are sequences represented by SEQ ID NO:1-4 or sequences represented by SEQ ID NO:5-8 or sequences represented by SEQ ID NO:9-12 or sequences represented by SEQ ID NO:13-16. The kit provided by the invention has the advantages of short detection time, strong specificity, high sensitivity, high detection accuracy and programmed reaction, is easy and convenient to qualify and is widely applied to conventional detection and epidemiological survey in clinic and ports.

The present invention developed and characterized in vitro and in vivo three full-length cDNA clones based on the alphavirus chikungunya, two sets of infectious clones based on CHIKV and replicons based on the principle used to generate the infection clones. Described herein is the method to generate such infective clones and replicons, their composition and their use as molecular tool, a delivery vehicle and vaccine.

The invention relates to the field of PCR detection kits, in particular to a kit for joint detection on a dengue fever virus and a chikungunya virus on the basis of a fluorescent PCR method. The kit for joint detection on the dengue fever virus and the chikungunya virus comprises a specific primer for the dengue fever virus, a dengue fever virus probe, a specific primer for the chikungunya virus and a chikungunya virus probe, wherein the specific primer for the dengue fever virus comprises a forward primer and a reverse primer; the specific primer for the chikungunya virus comprises a forward primer and a reverse primer. The kit provided by the invention specifically relates to two pairs of specific PCR primers and probers for respectively specifically amplifying the dengue fever virus and the chikungunya virus, the two pairs of the specific PCR primers can amplify the viruses simultaneously in a same PCR reaction system, multi-PCR detection is achieved, and not only is operation simple and convenient, but also the detection time is greatly shortened.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.

The invention discloses a cyclocompound of tetrahydropyrrole and dihydroimidazolone as well as preparation and pharmaceutical application thereof. The cyclocompound is a compound shown in a formula (I), an isomer or pharmaceutically acceptable salt thereof. The compound, isomer or pharmaceutically acceptable salt thereof can be applied to preparation of medicines used for preventing or treating related diseases (such as dengue fever, dengue hemorrhagic fever, dengue shock syndrome, Zika, Chikungunya, Japanese encephalitis, yellow fever, hepatitis C and West Nile disease) caused by a dengue fever virus and related viruses. (The formula (I) is described in the specification).

The invention belongs to the field of drug research and development, and relates to an antiviral traditional Chinese medicine composition and a preparation method and application thereof. The composition comprises Mongolian dandelion herb, root of sessile stemona and Indian iphigenia bulb and further optionally comprises root of lobed kudzuvine, rhizome of largehead atractylodes and root of blackend swallowwort, and can be prepared into appropriate pharmaceutically acceptable drug forms as needed. The composition has high resistance activity to strains of various acute infectious diseases and has good drug safety; as in-vitro(cell) pharmacodynamic test and in-vivo experiment result proved, the composition has effective broad-spectrum antiviral effect to viruses of influenza A H1N1, H7N7 and H9N2, Zika virus, Dengue fever type I and type II viruses, Chikungunya virus and the like; in addition, the composition can be developed into an oral broad-spectrum plant compound resisting various infectious viruses, which will be the major innovative breakthrough of clinic treatment in the related disease field.